Elicit Enters Pharma Target Screening
elicitorg · x · 2026-07-18
Orion Pharma is integrating Elicit into early-stage drug discovery decisions, specifically for target prioritization. The Elicit team notes that tasks previously taking scientists weeks to manually search, read, and synthesize literature can now be completed faster and cover a broader research scope.
The post mentions that Orion started using Elicit for Reports and Systematic Literature Reviews, later expanding into more workflows following the release of Research Agent. Client feedback indicates that what used to be a "paper by paper" process now takes less time, enabling the same team to evaluate more targets and make more confident go/no-go decisions.
Related event: Orion Pharma Brings Elicit Into Early Drug Research(3 posts)→
More from Companies & People
- A post says AI teams should drop the research scientist vs engineer split — jsuarez · 2026-07-22
- PNAS special issue on generative AI law covers safety, copyright and governance — chrmanning · 2026-07-22
- Prescience launches publicly as an AI-native health insurance company — ycombinator · 2026-07-22
- SF AI crowd swaps poker for a bullet and bughouse chess night — Jackyhuang · 2026-07-22
- Polymarket puts Anthropic’s year-end IPO odds at 64% amid patent suit — Polymarket · 2026-07-22
- University of Tennessee sues Anthropic over machine learning and neuromorphic patents — Polymarket · 2026-07-22